Safety and Efficacy of VAY736 in Patients With Primary Sjogren's Syndrome (pSS)
NCT02962895
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
190
Enrollment
INDUSTRY
Sponsor class
Conditions
Primary Sjogren Syndrome
Interventions
BIOLOGICAL:
VAY736
OTHER:
Placebo
Sponsor
Novartis Pharmaceuticals